title: Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
abstract: Total anti-gp120 antibodies (total anti-gp120 Abs) were purified from a pool of four human immunodeficiency virus-positive (HIV+) sera by affinity chromatography on a gp120SF2-Sepharose column and exhibited both type- and group-specific neutralizing activities. To dissect the epitope specificity of the group-specific neutralizing antibodies, CD4 attachment site-specific antibodies (CD4-site Abs) were isolated from total anti-gp120 Abs by using a CD4-blocked gp120SF2-Sepharose column. The CD4-site Abs exhibited group-specific neutralizing activities. Another approach to dissecting type- and group-specific neutralizing activities of total anti-gp120 Abs was to separate the third variable region (V3)-specific antibodies (V3-region Abs) from non-V3-region-specific antibodies (non-V3 Abs). The results indicated that V3-region Abs exhibited type-specific neutralizing activities, whereas non-V3 Abs exhibited group-specific neutralizing activities. By comparing the neutralizing activities of V3-region Abs to those of non-V3 Abs, we concluded that V3-region Abs are more effective than non-V3 Abs in neutralizing a specific HIV isolate. Collectively, this study indicates that group-specific neutralizing anti-gp120 antibodies are specific for the CD4 attachment site.
authors.affiliation: IDEC Pharmaceuticals Corporation, La Jolla, CA 92037.
authors.forename: C Y
authors.initials: CY
authors.lastname: Kang
authors.forename: P
authors.initials: P
authors.lastname: Nara
authors.forename: S
authors.initials: S
authors.lastname: Chamat
authors.forename: V
authors.initials: V
authors.lastname: Caralli
authors.forename: T
authors.initials: T
authors.lastname: Ryskamp
authors.forename: N
authors.initials: N
authors.lastname: Haigwood
authors.forename: R
authors.initials: R
authors.lastname: Newman
authors.forename: H
authors.initials: H
authors.lastname: Köhler
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology*; D000595:Amino Acid Sequence; D000936:Antigen-Antibody Complex; D015704:CD4 Antigens / Q000276:immunology*; D002846:Chromatography, Affinity; D015483:HIV Antibodies / Q000276:immunology* / Q000302:isolation & purification; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology
chemical_list: D000936:Antigen-Antibody Complex; D015704:CD4 Antigens; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D010455:Peptides